CD-801
/ Shanghai Changzheng Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 22, 2024
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
(clinicaltrials.gov)
- P1 | N=37 | Not yet recruiting | Sponsor: Shanghai Changzheng Hospital | Initiation date: May 2024 ➔ Aug 2024
Metastases • Trial initiation date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
August 27, 2024
The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Shanghai Changzheng Hospital
Metastases • New P1 trial • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor
May 20, 2024
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
(clinicaltrials.gov)
- P1 | N=37 | Not yet recruiting | Sponsor: Shanghai Changzheng Hospital
Metastases • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
October 23, 2023
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Shanghai Changzheng Hospital
Metastases • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1